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Abstract
Background: In unexplained and mild male factor subfertility, both intrauterine insemination (IUI)
and in-vitro fertilisation (IVF) are indicated as first line treatments. Because the success rate of IUI
is low, many couples failing IUI subsequently require IVF treatment. In practice, it is therefore
important to examine the comparative outcomes (live birth-producing pregnancy), costs, and cost-
effectiveness of primary offer of IVF, compared with primary offer of IUI followed by IVF for
couples failing IUI.
Methods: Mathematical modelling was used to estimate comparative clinical and cost effectiveness
of either primary offer of one full IVF cycle (including frozen cycles when applicable) or "IUI + IVF"
(defined as primary IUI followed by IVF for IUI failures) to a hypothetical cohort of subfertile
couples who are eligible for both treatment strategies. Data used in calculations were derived from
the published peer-reviewed literature as well as activity data of local infertility units.
Results: Cost-effectiveness ratios for IVF, "unstimulated-IUI (U-IUI) + IVF", and "stimulated IUI (S-
IUI) + IVF" were £12,600, £13,100 and £15,100 per live birth-producing pregnancy respectively.
For a hypothetical cohort of 100 couples with unexplained or mild male factor subfertility,
compared with primary offer of IVF, 6 cycles of "U-IUI + IVF" or of "S-IUI + IVF" would cost an
additional £174,200 and £438,000, representing an opportunity cost of 54 and 136 additional IVF
cycles and 14 to 35 live birth-producing pregnancies respectively.
Conclusion: For couples with unexplained and mild male factor subfertility, primary offer of a full
IVF cycle is less costly and more cost-effective than providing IUI (of any modality) followed by IVF.
Background
In any health care system, cost-effective commissioning of
health care in order to maximise population health out-
comes with the minimum possible resource use, is an
important consideration. The UK National Institute for
Clinical Excellence (NICE) [1] recommends offer of up to
six cycles of Unstimulated Intrauterine Insemination (U-
IUI) for couples with unexplained or mild male factor
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gested overall savings to the NHS from a "switch" of activ-
ity from Stimulated IUI (S-IUI) to U-IUI, which was also
recommended [2]. These calculations however were based
on 'head-to-head' comparisons between S-IUI and U-IUI
and completely ignored the cost implications of the fact
that many couples who fail IUI will subsequently require
in-vitro fertilisation (IVF) treatment.
Even if some health care interventions may have a rela-
tively low cost per treatment session, they could be less
cost-effective compared to alternative treatments with a
higher cost per treatment session, but also better clinical
effectiveness. It is therefore legitimate to examine critically
whether funding for IUI allows better management of cur-
rent demand, or whether it increases activity and overall
associated healthcare expenditure for those couples who
are eligible for both treatment strategies [3]. We therefore
constructed a mathematical model to evaluate the cost-
effectiveness of provision of IUI followed by IVF com-
pared to primary offer of IVF for patients who according
to NICE are eligible for both treatment strategies.
Methods
Model construction
The structure of the generic model is presented in Figure
1. The model emulates the clinical experience of a hypo-
thetical cohort of 100 couples with unexplained or mild
male factor subfertility by different treatment strategy,
including, when applicable, the transition from one to
another treatment stage or strategy. The outcome exam-
ined was live birth-producing pregnancy. Three different
scenarios were used sequentially, relating to comparisons
of primary offer of IVF with three possible modalities of
IUI: U-IUI, S-IUI (gonadotrophin-stimulated) and C-IUI
(clomifene-stimulated). Each of the three scenarios
allowed for estimation of activity and outcomes for offer
of up to six IUI cycles, as per NICE guidance [1].
The EVEREST checklist for health economic studies was
used as a reference to our study design (Additional File 1).
Assumptions used in the model
Assumptions used in the calculations are presented in
Table 1. Evidence to populate the models was derived
from peer-reviewed literature and, in the absence of such
literature data, based on activity data of local subfertility
unit. For estimates from the literature, we have used the
excellent systematic review conducted by NICE to under-
pin their 2004 guidance on subfertility treatments. In
addition, we have searched MEDLINE for any more recent
studies on live birth rate (LBR) of S-IUI, U-IUI, and C-IUI.
Relevant studies are referenced in relevant parts of the
manuscript.
The structure of the generic modelFigure 1
The structure of the generic model. U-IUI: Unstimulated IUI S-IUI: Gonadotrophin stimulated IUI C-IUI: Clomifene stim-
ulated IUI ART: Assisted reproductive technique LBR: Live birth rate
Cost of IUI
£
IUI or S-IUI * 0 - 6 cycles
(different LBR rates / cycle assumed)
Discontinued ART
(@ 10 %)
(due to natural pregnancy
or change in circumstances)
Cost of IVF
£
Live birth achieved
%y
IVF X 1 "full" cycle
[(100 - x) * 90% ]
Failed IUI cycles
(100 - x) %
Live birth achieved
x %
Couples eligible for IUI or IVF
Total live birth 
from IUI+IVF
Total cost of 
IUI+IVFPage 2 of 11
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BMC Health Services Research 2006, 6:80 http://www.biomedcentral.com/1472-6963/6/80A cycle of IVF included a fresh cycle, and when applicable,
(i.e. in couples who had additional viable embryos pre-
served at the time of the fresh embryo transfer, and subse-
quently did not achieve pregnancy through the fresh
cycle) frozen embryo transfer (FET) cycles. All estimates
assume a "steady state" between incident need and supply
of services, and a "steady state" in progression (e.g. wait-
ing or natural lag times) for transition to a subsequent
treatment stage or strategy.
Average LBR values for fresh as well as FET IVF cycles were
derived from the UK's Human Fertilisation and Embryol-
ogy Authority (HFEA) population-based register 1995 to
1999 as used by NICE [1]. As supported by evidence, it
was assumed that the average LBR derived from HFEA
data is applicable to couples accessing IVF after previous
failed IUI attempts.
Unlike IVF, there is no population-based data on the effec-
tiveness (LBR) of S-IUI. Therefore, two sets of values for
LBR were considered either based on, or informed by, data
derived from the experience of a local unit, which during
the period of 1993 to 2003 provided 676 cycles of S-IUI
to 334 different women aged < 40 years of age, and with a
range of uptake of 1 to 5 cycles (Additional File 2) [5].
Firstly, an average LBR value for S-IUI of 7% per cycle,
independently of treatment cycle order was used. Sec-
ondly, LBR values of 10%, 6%, 4%, 4%, 2%, and 2% for
the 1st to the 6th cycle respectively were used. The first sce-
nario (mean effectiveness independent of cycle order) is
reasonable, as small numbers did not allow for confident
calculation of LBR for subsequent to the first cycle. The
second scenario reflects both the actual experience of the
local unit [5], and peer-reviewed evidence [6-10], indicat-
ing decreasing effectiveness of IUI with order of cycle.
Unlike S-IUI, U-IUI has, at least up until the publication
of the NICE guidelines [1] in 2004, been practiced very
infrequently in the UK, therefore, there were no national
or local data of relevance to U-IUI outcomes. Given this,
the LBR of U-IUI was estimated to be half of that of S-IUI
[11]. Similarly, the LBR for C-IUI was assumed to be 3%,
i.e. 60% lower than of S-IUI, as suggested by a Cochrane
review [12].
It was assumed that on average 10% of couples who fail
IUI treatment (irrespective of the number of IUI cycles
received) would drop out of subfertility treatment. This
was based on informed judgement, to reflect potential
changes in childbearing intentions or partnership status.
Cost calculations
Costs relate to resources directly associated with fertility
treatment, and exclude costs from potential complica-
tions and/or multiple pregnancy. The average costs per
cycle of IVF, FET, U-IUI, and S-IUI used were the ones used
in NICE's economic model [1], and were consistent with
NHS costs for these treatments locally. In the absence of a
Table 1: Assumptions underlying the modelling and their corresponding sources
Assumption Source
There is an 1:1 ratio between "fresh" and "frozen" cycles, assuming 25% 
of couples have 0 FET, 50% have 1 FET and 25% have 2 FET
Hypothetical assumption, based on informed judgement
IVF and IVF/ICSI ratio is 1:1 Hypothetical assumption, based on informed judgement
100% compliance and 0% drop out with IUI treatment Hypothetical assumption, based on informed judgement
Effectiveness
LBR following a "full" IVF (IVF/ICSI) cycle is 19.26% (all ages) HFEA 1995–19991
LBR following "frozen" IVF (IVF/ICSI) cycle is 10.40% (all ages) HFEA 1995–19991
LBR following unstimulated IUI is 3.5% per cycle Informed judgement, based on local data on effectiveness of stimulated 
IUI and by halving this, peer-reviewed literature11
LBR following gonadotrophin-stimulated IUI is 7% per cycle Based on local activity data
LBR following clomifene- stimulated IUI is 3% Informed judgement, local activity data, and peer reviewed literature 12
Cost
-Cost of "fresh" IVF (IVF/ICSI) is £3,214 assuming 50% of "fresh" cycles 
will be ICSI cycles -Cost of "frozen" IVF (IVF/ICSI) is £450 -Cost of 
unstimulated IUI is £449 -Cost of stimulated IUI is £1005 -Cost of 
Clomiphene stimulated IUI is £752
NICE estimates1
90% of couples who fail IUI proceed to IVF Hypothetical, based on informed judgement
LBR: Live birth rate
FET: Frozen embryo transferPage 3 of 11
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BMC Health Services Research 2006, 6:80 http://www.biomedcentral.com/1472-6963/6/80relevant information in NICE's economic model, it was
assumed that the cost of C-IUI is approximately 'half way'
between cost of U-IUI and S-IUI (£752), based on local
expert opinion and knowledge of drug costs.
Cost-effectiveness
The perspective used in the cost-effectiveness analysis was
that of the health service. The total cost to the health serv-
ice was taken as the sum of the costs of the IUI and the IVF
activity generated by each scenario.
Incremental cost-effectiveness ratio (ICER) was calculated
as the ratio of the difference in the combined cost of "IUI
+ IVF" strategies minus the cost of IVF, divided by the dif-
ference in number of live birth-producing pregnancies for
each treatment strategy. In this instance ICER values there-
fore indicate the additional cost associated with a given
treatment strategy in order to produce a single additional
live birth-producing pregnancy.
Sensitivity analysis
Sensitivity analysis was undertaken to examine the robust-
ness of the modelling and to study the impact of plausible
variation in the variables for which uncertainty was
judged to be higher (e.g. those least well supported by
population-based data or peer-reviewed publications).
Therefore, the estimates of U-IUI, S-IUI and C-IUI were
varied sequentially, using different value estimates from
the literature, or in the absence of alternative literature
estimates, based on local experience, expert opinion, or
reasonable assumptions about the plausible range of
uncertainty around "best estimate" values. More specifi-
cally:
• for S-IUI
An alternative LBR estimate of 8.7% per cycle (independ-
ently of cycle order) was used based on Goverde et al [13].
• for U-IUI
An alternative LBR estimate of 4.4% per cycle (independ-
ently of cycle order) was used, assuming the LBR of U-IUI
to be half of that of S-IUI [11]. In addition, LBR values of
5%, 3%, 2%, 2%, 2%, 2% for the 1st to the 6th cycle respec-
tively were also used for U-IUI, again assuming the effec-
tiveness of U-IUI to be half of that of S-IUI [11]. Lastly, a
third estimate of an average LBR of 2% per cycle was used
based on local clinical experience and expert opinion.
• for C-IUI
An alternative LBR estimate of 6.6% per cycle (independ-
ently of cycle order) was used based on reasonable
assumption of having LBR of C-IUI in between LBR values
of S-IUI and U-IUI. Additionally, an average LBR value of
2.5% per cycle was used, based on local experience and
expert opinion.
Results
For a hypothetical cohort of 100 couples with unex-
plained or mild male factor subfertility, the cost of pri-
mary offer of one full cycle of IVF would be £321,700,
with a cost-effectiveness ratio of £12,600/live birth-pro-
ducing pregnancy (Table 2).
Cost-effectiveness of 'head-to-head' comparison of 
primary IUI vs. primary IVF
Primary offer of one to six cycles of U-IUI or C-IUI, or up
to three cycles of S-IUI is less costly than one cycle of fresh
IVF. However, when comparing the cost-effectiveness of
U-IUI, S-IUI and C-IUI to one full cycle of IVF, IVF is more
cost-effective (Table 2).
Cost-effectiveness of "IUI + IVF" vs. primary IVF
Assuming a mean U-IUI LBR of 3.5% per cycle
For six cycles of U-IUI the cost of IUI followed by IVF
would be £495,900 with a cost-effectiveness ratio of
£13,100/live birth-producing pregnancy (Table 2). Com-
pared to primary offer of IVF, the ICER for offer of one to
six cycles of U-IUI followed by IVF (for IUI failures) would
be £18,000 to £14,200 per live birth-producing preg-
nancy.
Assuming a mean S-IUI LBR of 7% per cycle
For one to six cycles of S-IUI per couple, the total cost of
"IUI+IVF" would range from £369,000 to £759,800,
equivalent to £13,000 to £15,100 per live birth-producing
pregnancy. The ICER would increase with increase in cycle
order (Table 2).
For one to six cycles of IUI, the "IUI + IVF" treatment strat-
egy would be more costly and less cost-effective than one
full cycle of IVF.
Figure 2 compares total cost and cost-effectiveness of U-
IUI to S-IUI. U-IUI is more cost-effective than S-IUI at any
cycle order.
Assuming a mean C-IUI LBR of 3% per cycle
Among the three IUI modalities, C-IUI (with the lowest
LBR) had the worst cost-effectiveness ratio and the worst
ICER.
When assuming that LBR of IUI (any modality) was
decreasing with cycle order, all above scenarios showed
consistently similar results, with higher cost and worst
cost-effectiveness and ICER values for "IUI+IVF" com-
pared to IVF only.
Opportunity costs
Table 3 shows the opportunity costs, in terms of number
of additional IVF cycles that could be purchased by the
cost difference of IUI (followed by IVF) compared to pri-Page 4 of 11
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Table 2: Cost, outcome, cost-effectiveness ratio and incremental cost-effectiveness ratio (ICER) of providing unstimulated IUI (U-IUI), gonadotrophin stimulated IUI (S-IUI) and 
clomifene stimulated IUI (C-IUI) to a hypothetical cohort of couples with unexplained or male factor subfertility.
U-IUI (LBR = 3.5%) Full cycle of IVF Overall
Order 
of cycle
No. of 
cycles
Live- birth 
Deli-very 
from IUI
Cost £ Cost/
outcome 
(£/delivery)
No. of couples 
having one full 
cycle of IVF
Live birth delivery 
from one full cycle 
of IVF
Cost £ Total live 
birth delivery 
(IUI+ IVF)
Total cost £ Total cost/total 
outcome 
(£/Delivery)
ICER
U-IUI (LBR-3.5%)
0 0 0 0 100 26 321,700 26 321,700 12,600 Ref
1 100 4 44,900 12,800 87 22 279,400 26 324,300 12,700 18,600
2 196 7 88,200 12,800 84 21 269,600 28 357,900 12,600 13,200
3 293 10 131,600 13,000 81 21 260,200 31 391,800 12,700 13,400
4 390 13 175,000 13,200 78 20 251,100 33 426,100 12,800 13,600
5 487 16 218,500 13,400 75 20 242,300 36 460,800 13,000 13,900
6 584 19 262,000 13,600 73 19 233,800 38 495,900 13,100 14,200
S-IUI (LBR = 7%)
0 0 0 0 100 26 321,700 26 321,700 12,600 Ref
1 100 7 100,500 14,400 84 21 269,300 28 369,800 13,000 24,000
2 193 14 194,000 14,400 78 20 250,400 33 444,400 13,300 17,500
3 286 20 287,900 14,700 72 19 232,900 38 520,800 13,700 16,600
4 380 25 382,300 15,200 67 17 598,900 42 598,900 14,100 17,300
5 475 30 477,200 15,700 63 16 678,600 46 678,600 14,600 17,800
6 570 35 572,400 16,200 58 15 759,800 50 759,800 15,100 18,300
C-IUI (LBR = 3%)
0 0 0 0 100 26 321,700 26 321,700 12,600 Ref
1 100 3 75,200 25,100 87 22 280,900 25 356,000 14,000 *
2 197 6 148,100 24,700 85 21 272,400 28 420,600 15,300 49,400
3 294 9 221,200 24,600 82 21 264,000 30 485,200 16,300 40,900
4 391 12 294,200 24,500 79 20 255,600 32 549,700 17,200 38,000
5 488 15 367,200 24,500 77 20 247,100 34 614,300 17,900 36,600
6 585 18 440,200 24,500 74 19 238,700 37 678,900 18,600 32,500
* It was not possible to estimate a meaningful ICER (ICER = (£356073-£321733)/(25.3–25.6) = -£114,467/Live birth-producing pregnancy as compared to full cycle of IVF).
Cost/unit; IVF = £3,214, U-IUI = £449, S-IUI = £1,005, C-IUI = £752Live birth delivery refers to live birth- producing pregnancyFigures are rounded to the nearest hundred
BMC Health Services Research 2006, 6:80 http://www.biomedcentral.com/1472-6963/6/80mary offer of IVF alone. Providing six cycles of U-IUI and
one full cycle of IVF to 90% of couples who failed IUI,
would increase subfertility related health care expenditure
by £174,200. If this amount was allocated for purchasing
of IVF, then an additional 54 couples would have access
to IVF and an additional 14 couples would achieve a live
birth-producing pregnancy. If six cycles of S-IUI were
offered instead of U-IUI, the otherwise avoidable cost to
the health care system would be an additional £438,000,
sufficient to otherwise fund 136 IVF cycles, and to enable
additional 35 couples to achieve live birth. If a smaller
number of IUI cycles is offered the opportunity costs
would be minimised, but the net difference would always
be in favour of the primary IVF strategy.
Sensitivity analysis
After considering different plausible LBR values for S-IUI,
U-IUI and C-IUI, the primary offer of IVF remained more
cost-effective than providing "IUI+IVF" (Table 4) and
associated with less opportunity cost (Table 5).
Discussion
The findings suggest that for couples with unexplained or
mild male factor subfertility, primary offer of a full IVF
cycle is less costly and more cost-effective than primary
offer of any IUI modality followed by IVF (for IUI fail-
ures). Importantly, the cost of primary IUI (any modality)
increases and its cost-effectiveness decreases with increas-
ing number of IUI cycles offered. Between S-IUI and U-
IUI, S-IUI followed by IVF was associated with higher cost
and lower cost-effectiveness compared with U-IUI fol-
lowed by IVF. The sensitivity analysis findings indicate
Cost and cost-effectiveness (per live birth-producing pregnancy) of different uptake of IUI and S-IUI among a hypothetical cohort of 100 couples eligible for both IUI and IVFFigu e 2
Cost and cost-effectiveness (per live birth-producing pregnancy) of different uptake of IUI and S-IUI among a hypothetical 
cohort of 100 couples eligible for both IUI and IVF. Assumes constant LBR of 7% and 3.5% for S-IUI and IUI.
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BMC Health Services Research 2006, 6:80 http://www.biomedcentral.com/1472-6963/6/80that the main finding of inferior cost-effectiveness of the
primary IUI, compared with primary IVF, is robust. A pre-
vious study on cost impact implications of the 2004 NICE
guidance has failed to reach similar conclusions, as it did
not accurately simulate real life patient experience and
clinical management [1].
In principle, a prospective randomised controlled trial
would have been a superior study design to answer this
study's research question. However, such a study would
have had to entertain certain practical obstacles, including
ethical clearance, and may not be forthcoming for many
years to come. At the same time resource allocation and
service development policy decisions have to be made
currently and in the near future. In the absence of RCT-
based evidence, mathematical modelling synthesising evi-
dence from various high quality sources is the only
rational way to support health care policy decision-mak-
ing [14].
Published data comparing the cost-effectiveness of IVF
versus IUI are scarce. Some studies indicate that IUI may
be more cost-effective than IVF in cases of unexplained
and moderate male subfertility [13,15-17]. However,
these studies have not accounted for the potential subse-
quent FET component of IVF strategies, which increases
their cost-effectiveness [17]. More importantly, these stud-
ies do not take into account the potential for eventual
"transfer" of most couples who fail IUI to IVF, a crucial
consideration by commissioners of healthcare services
when both IUI and IVF are funded from the same budget
(as is the case in the UK NHS).
The majority of the literature on IUI effectiveness comes
from uncontrolled retrospective case series and cohort
designs, could overestimate treatment effectiveness
because of selection bias and consideration of clinical
pregnancy as opposed to live birth as the study outcome.
Also, the number of abandoned cycles is generally
excluded from the denominator, leading to inflated esti-
mates of effect [11]. A further problem is that the reported
effectiveness of IUI is very variable, ranging from small
integer numbers to up to over 30%. This heterogeneity
may be due to factors including differences in study pop-
ulations, ovarian stimulation regimes, the number of
inseminations per cycle, the timing of insemination, and
Table 3: Cost difference, number of additional full cycles of IVF that could be purchased and corresponding additional number of live 
birth-producing pregnancies by the estimated cost difference of providing "IUI+IVF" compared to primary offer of IVF
"IUI + IVF" for those failing IUI
IUI modality One cycle 
of IUI
Two cycles 
of IUI
Three cycles 
of IUI
Four cycles 
of IUI
Five cycles 
of IUI
Six cycles 
of IUI
U-IUI (LBR = 3.5%)
Cost difference "IUI+IVF" vs. primary IVF £2,600 £36,100 £70,100 £104,400 £139,100 £174,200
No of IVF cycles that would be purchased by the 
cost difference
1 11 22 32 43 54
No of live birth-producing pregnancies expected 
from IVF cycles that would have been purchased by 
the cost difference
0 4 6 8 11 14
S-IUI (LBR = 7%)
Cost difference "IUI+IVF" vs. primary IVF £48,100 £122,600 £199,100 £277,200 £356,900 £438,000
No of IVF cycles that would be purchased by the 
cost difference
15 38 62 86 111 136
No of live birth-producing pregnancies expected 
from IVF cycles that would have been purchased by 
the cost difference
4 10 16 22 28 35
C-IUI (LBR = 3%)
Cost difference "IUI+IVF" vs. primary IVF £34,300 £98,900 £163,400 £228,000 £292,600 £357,200
No of IVF cycles that would be purchased by the 
cost difference
11 31 51 71 91 111
No of live birth-producing pregnancies expected 
from IVF cycles that would have been purchased by 
the cost difference
3 8 13 18 23 28
Figures are rounded to the nearest hundred.Page 7 of 11
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BMC Health Services Research 2006, 6:80 http://www.biomedcentral.com/1472-6963/6/80methods of sperm preparation [18]. Also, the reported tri-
als involved an exceedingly small fraction of the very great
number of patients world-wide undergoing treatment, so
generalisations have to be cautious [19]. Given the above
limitations of published evidence, we used local IUI activ-
ity data as the main source of our data in relation to the
effectiveness of IUI, but complemented those with differ-
ent sets of estimates in sensitivity analysis. The results
obtained using local current data could better reflect the
likely current UK practice in a "real life" situation, and for
an unselected population.
We used a mean LBR value of 7% for S-IUI based on local
experience on 676 cycles of S-IUI over 10 years. In most
studies the pregnancy rate per cycle of S-IUI is approxi-
mately 10% [20-22]. A prospective randomised study
from The Netherlands showed that the average LBR of S-
IUI of 8.7% per cycle [13]. NICE in its economic model
has used results of an RCT from the US [23] reporting
cumulative pregnancy rates of 33% for S-IUI for an aver-
age of 5.6 cycles. In our model, if the cumulative LBR for
five and six cycles of S-IUI is considered, it equates to 30%
and 35% respectively, and as such our assumptions are
comparable to the order of the estimates used by NICE.
The effectiveness (LBR) of IUI was judged to be 3.5% per
treatment cycle -this represents an informed judgement,
based on the literature. Many experts would support that
this is actually a high estimate, but we preferred to use a
"generous" estimate. If the true estimate is lower, any bias
introduced from this assumption would have favoured
the cost-effectiveness of U-IUI, and would have made IVF
less cost effective, i.e. if a lower LBR value for U-IUI was
used, the results would have been even more favourable
for primary offer of IVF as the preferred treatment strategy.
We used average success rates rather than age- and indica-
tion-specific LBRs. Maternal age affects outcomes of IUI,
but so does for IVF [1]. Similarly, different subfertility
indications are associated with different success rates for
IUI, but again the same is true for IVF. Therefore, the lack
of stratification (by age or indication) is very unlikely to
influences the results for either modality. In any case, the
hypothetical cohort of 100 couples can be assumed to
have an identical case mix in terms of age and indication
stratification, whichever treatment strategy is offered.
The modelling of costs has concentrated on the nominal
cost of IVF and IUI. Other essential aspects of the service
Table 4: Sensitivity analysis estimates of incremental cost-effectiveness ratios (ICER) of providing "IUI+IVF" compared to primary 
offer of IVF, varied sequentially.
Varied variables Source of assumption ICER (£/live birth-producing pregnancy)
1 cycle 
of IUI
2 cycles 
of IUI
3 cycles 
of IUI
4 cycles 
of IUI
5 cycles 
of IUI
6 cycles 
of IUI
S-IUI
LBR = 8.7% Goverde et al 13 £10,400 £10,900 £11,600 £12,300 £13,000 £13,800
LBR varying by cycle order* Local unit's experience and peer-reviewed 
literature 6–10
£7,700 £12,300 £16,800 £19,900 £24,300 £28,300
U-IUI
LBR = 4.4% LBR of U-IUI as half of that of S-IUI11 £0 £7,500 £8,700 £9,300 £9,800 £10,200
LBR = 2% Local experience and expert opinion ¶ £91,700 £42,400 £35,700 £33,300 £32,100
LBR varying by cycle order± LBR of U-IUI as half of that of S-IUI11 £41,600 £40,400 £47,600 £51,900 £54,900 £57,100
C-IUI
LBR = 6.6% Reasonable assumption, LBR of C-IUI 
between the values of LBR of U-IUI and S-IUI
£9,500 £10,500 £10,700 £10,800 £10,900 £10,900
LBR = 2.5% Local experience and expert opinion ¶ £81,900 £53,900 £46,900 £43,700 £41,900
* LBR of S-IUI of 10%, 6%, 4%, 4%, 2%, 2% for cycles 1 to 6 respectively
± LBR of U-IUI of 5%, 3%, 2% 2%, 2%, 2% for cycles 1 to 6 respectively.
¶It was not possible to estimate a meaningful ICER because of very small denominator in case of one cycle of U-IUI (when LBR = 2%) and one cycle 
of C-IUI (when LBR = 2.5%) as compared to 1 full cycle of IVF.
ICER was estimated based on cost and effectiveness of "IUI+IVF" compared to full cycle of IVF.
Figures are rounded to the nearest hundredPage 8 of 11
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ments, counselling) have not been calculated, because
they were assumed to be already occurring (i.e. requiring
no 'new' money) and to be similar to both treatment strat-
egies. The cost associated with complications, such as
multiple gestation and birth, were also not included in
calculations. Evidence suggests that there is no statistically
significant difference in the incidence of ovarian hyper-
stimulation syndrome (OHSS) and multiple pregnancy
rate between S-IUI and IVF [13]. As such, it is unlikely that
inclusion of the costs of complications would have had an
impact on the comparative cost-effectiveness of S-IUI and
IVF.
Lastly, anecdotally, undergoing IUI followed by IVF may
be more psychologically distressing to the couple com-
pared to IVF alone, as it may be more frustrating to have,
on average, comparatively more failed treatment cycles -
although direct evidence about this assumption is lacking.
However, some patients may have a positive preference
for IUI or an aversion for IVF (on philosophical, or reli-
gious grounds). We acknowledge that traditional meth-
Table 5: Sensitivity analysis estimates of cost difference, and the additional number of live birth-producing pregnancies by the 
estimated cost difference of providing "IUI+IVF" compared to primary offer of IVF, varied sequentially.
Variable varied Cost difference £ [("IUI+IVF") - IVF]
S-IUI 1 cycle of IUI 2 cycles of IUI 3 cycles of IUI 4 cycles of IUI 5 cycles of IUI 6 cycles of IUI
LBR = 8.7% £43,100 £111,900 £183,400 £257,400 £333,800 £412,200
LBR varying by cycle order* £39,400 £114,200 £199,500 £287,200 £379,900 £474,400
U-IUI
LBR = 4.4% £0 £30,700 £62,100 £94,100 £126,600 £159,700
LBR = 2% £6,900 £45,300 £83,700 £122,300 £161,000 £199,900
LBR varying by cycle order± £53,800 £141,100 £233,400 £326,800 £420,300 £514,000
C-IUI
LBR = 6.6% £23,900 £76,300 £128,900 £181,600 £234,200 £286,800
LBR = 2.5% £35,800 £102,100 £168,400 £234,700 £301,000 £367,300
No. of live births expected from full cycles of IVF that could be purchased by the estimated cost 
difference
S-IUI
LBR = 8.7% 3 9 15 20 27 33
LBR varying by cycle order* 3 9 16 23 30 38
U-IUI
LBR = 4.4% 0 2 5 7 10 13
LBR = 2% 1 4 7 10 13 16
LBR varying by cycle order± 4 11 19 26 33 41
C-IUI
LBR = 6.6% 2 6 10 14 19 23
LBR = 2.5% 3 8 13 19 24 29
* LBR of S-IUI of 10%, 6%, 4%, 4%, 2%, 2% for cycles 1 to 6 respectively
± LBR of U-IUI of 5%, 3%, 2% 2%, 2%, 2% for cycles 1 to 6 respectively.
Figures of cost differences are rounded to the nearest hundred.Page 9 of 11
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study, are not useful tools when dealing with philosophi-
cally-grounded patient preferences – which however are
exceptional, rather than the norm.
Conclusion
Our study indicates that for couples with unexplained or
mild male factor subfertility, a primary treatment offer of
any modality of IUI instead of primary offer of IVF is cost-
ineffective, and therefore associated with considerable
opportunity costs. The additional and avoidable costs
incurred put pressure on the health care system to cope
with extra demand and activity for a treatment of low
effectiveness, making the wider availability of the most
effective treatment (IVF) more difficult, and thus disad-
vantaging couples who could have otherwise benefited
from it.
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